Antibody-drug conjugates are revolutionizing the therapeutic landscape for NSCLC. Are you up to date?    Credit available for this activity expires: 1/24/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999749?ecd=bdc_podcast_libsyn_mscpedu